VELETRI

Opinions on drugs - Posted on Dec 12 2014

Reason for request

Inclusion

Clinical Benefit

Substantial

The actual benefit of VELETRI is substantial in PAH.

Clinical Added Value

no clinical added value

In PAH :

VELETRI (epoprostenol), a hybrid medicine based on FLOLAN and its generics which has a new pharmaceutical form extending the stability of the solution at room temperature, does not provide any improvement in actual benefit (level V,non-existent) in comparison with these proprietary medicinal products.